Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Monday, July 15th, RTT News reports. Stockholders of record on Tuesday, August 27th will be given a dividend of 0.95 per share on Tuesday, September 10th. This represents a $3.80 annualized dividend and a dividend yield of 2.98%. The ex-dividend date of this dividend is Monday, August 26th.
Johnson & Johnson has increased its dividend payment by an average of 6.3% annually over the last three years and has increased its dividend annually for the last 56 consecutive years. Johnson & Johnson has a dividend payout ratio of 46.7% meaning its dividend is sufficiently covered by earnings. Analysts expect Johnson & Johnson to earn $9.09 per share next year, which means the company should continue to be able to cover its $3.80 annual dividend with an expected future payout ratio of 41.8%.
JNJ stock opened at $127.73 on Friday. The company’s 50-day simple moving average is $132.65 and its 200-day simple moving average is $136.53. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The firm has a market cap of $347.13 billion, a P/E ratio of 15.61, a PEG ratio of 2.23 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same period in the prior year, the company posted $2.10 EPS. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
In other Johnson & Johnson news, Director Marillyn A. Hewson acquired 3,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was bought at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the acquisition, the director now owns 3,000 shares in the company, valued at $419,040. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.23% of the stock is currently owned by corporate insiders.
Several research analysts recently weighed in on the stock. Raymond James reduced their price target on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research report on Wednesday, July 17th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Credit Suisse Group set a $156.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Thursday, July 18th. Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, May 28th. They set a “buy” rating for the company. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target for the company. in a research report on Thursday, July 18th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $148.56.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.